Arginine-vasopressin for Shock in Premature Infants
Author Information
Author(s): Sascha Meyer, Sven Gottschling, Ali Baghai, Donald Wurm, Ludwig Gortner
Primary Institution: University Children's Hospital of Saarland
Hypothesis
The study aims to assess the efficacy of arginine-vasopressin (AVP) as a rescue therapy in catecholamine-refractory septic and non-septic shock in extremely low birth weight infants with acute renal injury.
Conclusion
AVP may be a promising rescue therapy in catecholamine-resistant shock in ELBW infants with acute renal injury.
Supporting Evidence
- AVP administration led to increased blood pressure and urine output in infants with septic shock.
- The mortality rate was lower in the septic group (1/3) compared to the non-septic group (3/3).
- AVP was administered continuously and adjusted based on clinical response.
Takeaway
This study looked at a medicine called AVP that helps tiny babies with serious blood pressure problems. It found that AVP can help some babies feel better when other treatments don't work.
Methodology
The study involved a prospective assessment of AVP therapy in six ELBW infants with catecholamine-refractory septic and non-septic shock.
Potential Biases
Potential bias due to the small number of participants and lack of control group.
Limitations
The study had a small sample size and did not measure AVP serum levels.
Participant Demographics
Six extremely low birth weight infants (mean birth weight 600 ± 30 g for septic and 770 ± 110 g for non-septic).
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website